Common Stock, par value $0.001 per share
- Symbol
- KAPA
- Exchange
- NYSEAMER
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Kairos Pharma, Ltd.
KAPANYSE_AMERICANEQUITYCurrent
Other Events
Item 8.01. Other Events. On June 4, 2026, Kairos Pharma, Ltd. (the “Company”) issued a press release providing a summary of the Company’s achievements for the first half of 2026, as well as key milestones the Company expects to reach by the end of 2026. A copy of the press release is furnished herewith as Exhibit 99.1.…
Recent company filings
- Other EventsNov 5, 2026
- Entry into a Material Definitive Agreement · Other EventsNov 3, 2026
- Other EventsOct 6, 2026
- Regulation FD DisclosureSep 14, 2026
- Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD DisclosureAug 21, 2026
Registered securities in this filing
Kairos Pharma, Ltd. · 8-K · Filed 2026-06-04
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events.
On
June 4, 2026, Kairos Pharma, Ltd. (the “Company”) issued a press release providing a summary of the Company’s achievements
for the first half of 2026, as well as key milestones the Company expects to reach by the end of 2026. A copy of the press release
is furnished herewith as Exhibit 99.1.
The
information in this Current Report on Form 8-K, including Exhibit 99.1 furnished herewith, is being furnished and shall not be deemed
“filed” for any purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or otherwise subject to the liabilities of such Section. The information in this Current Report on Form 8-K shall not be deemed to be
incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly
set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders LOS ANGELES, June 4, 2026 - (Business Wire) - Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, provides a mid-year update for 2026 and a look ahead to the rest of the year in a letter to shareholders from CEO John Yu, M.D.: To our valued Kairos Pharma Shareholders, As we move toward the close of the second quarter, Kairos has been focused on adding some potentially impactful new development candidates to our existing pipeline. We announced the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. The Company will be acquiring the worldwide rights for a highly differentiated, clinical-stage oncology asset targeting non-small cell lung cancer (NSCLC) and esophageal and gastric cancer: CL-741, a Phase 1-ready, orally available type IIb c-MET kinase inhibitor. CL-741 is a Phase 1-ready therapeutic candidate targeting EGFR-mutated…
Open exhibit ↗